MEDP

SEC source: 0001567619-20-021629 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,519,000

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2020.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $140.00 to $141.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0000899243-20-034977 · doc4.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,522,547

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on December 3, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on December 3, 2020.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $140.00 to $140.295. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0000899243-20-034976 · doc4.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,522,547

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2020.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $140.00 to $140.295. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0000899243-20-034560 · doc4.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,555,807

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2020.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $140.00 to $150.57. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0000899243-20-034558 · doc4.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,555,807

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on December 3, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on December 3, 2020.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $140.00 to $150.57. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-20-021199 · doc1.xml · derivative · entry 3

GEIGER JESSE J · CIK 0001677399 · CFO & COO, Lab Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock · 4,200 shares

Expires 2023-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Each option vested on August 10, 2020.

SEC source: 0001567619-20-021199 · doc1.xml · nonDerivative · entry 2

GEIGER JESSE J · CIK 0001677399 · CFO & COO, Lab Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,382

SEC source: 0001567619-20-021199 · doc1.xml · nonDerivative · entry 1

GEIGER JESSE J · CIK 0001677399 · CFO & COO, Lab Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,582

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-021036 · doc1.xml · derivative · entry 3

EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 10,000 shares

Expires 2024-08-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Each option vested on August 5, 2019.

SEC source: 0001567619-20-021036 · doc1.xml · nonDerivative · entry 2

EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,854

F1 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $140.00 to $140.65. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-20-021036 · doc1.xml · nonDerivative · entry 1

EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,854

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-020608 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,771,855

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020, as amended on August 27, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020, as amended on August 27, 2020.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $130.00 to $131.37. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-20-020607 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,771,855

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020, as amended on August 27, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020, as amended on August 27, 2020.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $130.00 to $131.37. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-20-019063 · doc1.xml · derivative · entry 2

EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,518 shares

Expires 2021-07-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option was granted on July 7, 2014 and vested in four annual installments of approximately 25% on each grant date anniversary.

SEC source: 0001567619-20-019063 · doc1.xml · nonDerivative · entry 1

EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,854

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-019061 · doc1.xml · derivative · entry 2

BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,037 shares

Expires 2021-07-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option was granted on July 7, 2014 and vested in four annual installments of approximately 25% on each grant date anniversary.

SEC source: 0001567619-20-019061 · doc1.xml · nonDerivative · entry 1

BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,216

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-017753 · doc1.xml · derivative · entry 2

BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,037

Underlying: Common Stock · 20,000 shares

Expires 2021-07-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option was granted on July 7, 2014 and vested in four annual installments of approximately 25% on each grant date anniversary.

SEC source: 0001567619-20-017753 · doc1.xml · nonDerivative · entry 1

BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,179

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-017665 · doc1.xml · derivative · entry 6

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2023-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Each option vested on August 10, 2020.

SEC source: 0001567619-20-017665 · doc1.xml · nonDerivative · entry 3

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 666,643

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-017665 · doc1.xml · derivative · entry 5

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 65,305

Underlying: Common Stock · 2,592 shares

Expires 2022-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock options subject to this exercise are fully vested and exercisable.

F1 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-20-017665 · doc1.xml · derivative · entry 4

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 92,118

Underlying: Common Stock · 1,851 shares

Expires 2021-06-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock options subject to this exercise are fully vested and exercisable.

F1 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-20-017665 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,785,855

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-20-017665 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,783,263

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the shares held by MPI. The Reporting Person may be deemed to indirectly own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-20-017664 · doc1.xml · derivative · entry 4

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,305

Underlying: Common Stock · 2,592 shares

Expires 2022-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock options subject to this exercise are fully vested and exercisable.

SEC source: 0001567619-20-017664 · doc1.xml · derivative · entry 3

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,118

Underlying: Common Stock · 1,851 shares

Expires 2021-06-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock options subject to this exercise are fully vested and exercisable.

SEC source: 0001567619-20-017664 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,785,855

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-017664 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,783,263

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-016319 · doc1.xml · derivative · entry 6

GEIGER JESSE J · CIK 0001677399 · CFO & COO, Lab Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,200

Underlying: Common Stock · 3,110 shares

Expires 2023-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Each option vested on August 10, 2020.

SEC source: 0001567619-20-016319 · doc1.xml · nonDerivative · entry 4

GEIGER JESSE J · CIK 0001677399 · CFO & COO, Lab Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,382

SEC source: 0001567619-20-016319 · doc1.xml · nonDerivative · entry 3

GEIGER JESSE J · CIK 0001677399 · CFO & COO, Lab Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,492

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-016323 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,781,412

F1 · kind: Represents distributions of MEDP shares in-kind to the holders of Medpace Investors, LLC's ("MPI") Incentive Units.

F1 · shares: Represents distributions of MEDP shares in-kind to the holders of Medpace Investors, LLC's ("MPI") Incentive Units.

F2 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-20-016321 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,781,412

F1 · kind: Represents distributions of MEDP shares in-kind to the holders of the Reporting Person's Incentive Units.

F1 · shares: Represents distributions of MEDP shares in-kind to the holders of the Reporting Person's Incentive Units.

SEC source: 0001567619-20-016319 · doc1.xml · derivative · entry 5

GEIGER JESSE J · CIK 0001677399 · CFO & COO, Lab Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,310

Underlying: Common Stock · 3,700 shares

Expires 2023-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Each option vested on August 10, 2020.

SEC source: 0001567619-20-016319 · doc1.xml · nonDerivative · entry 2

GEIGER JESSE J · CIK 0001677399 · CFO & COO, Lab Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,382

SEC source: 0001567619-20-016319 · doc1.xml · nonDerivative · entry 1

GEIGER JESSE J · CIK 0001677399 · CFO & COO, Lab Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,082

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-016142 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,790,766

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $121.02 to $123.07. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-20-016141 · doc1.xml · nonDerivative · entry 3

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,790,766

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $121.02 to $123.07. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-20-016142 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,792,800

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $122.57 to $124.58. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-20-016141 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,792,800

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $122.57 to $124.58. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-20-016012 · doc1.xml · nonDerivative · entry 3

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,806,689

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $120.53 to $124.41. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-20-016007 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,806,689

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $120.53 to $124.41. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-20-016012 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,818,286

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $122.23 to $126.46. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-20-016007 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,818,286

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $122.23 to $126.46. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-20-015896 · doc1.xml · nonDerivative · entry 3

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,837,189

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $123.08 to $126.09. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-20-015895 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,837,189

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $123.08 to $126.09. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-20-015896 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,861,493

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 4, 2020.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $125.15 to $127.04. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-20-015895 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,861,493

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $125.15 to $127.04. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-20-015812 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,880,306

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $125.965 to $128.89. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.